Research programme: mucositis therapeutics - Sinopia Biosciences
Latest Information Update: 23 Sep 2024
At a glance
- Originator Sinopia Biosciences
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mucositis
Most Recent Events
- 12 Sep 2024 Sinopia Biosciences receives a phase II SBIR grant from the National Institute of Dental and Craniofacial Research (NIDCR) for oral mucositis program to lead discovery and optimization
- 01 Oct 2021 Preclinical trials in Mucositis in USA (unspecified route) (Sinopia Biosciences pipeline, October 2021)